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Abstract. The prognosis of colorectal cancer depends on the 
stage of the disease. However, even within the same stage there 
may be different outcomes in terms of recurrence and survival. 
Therefore, it is clear that as well as pathological stage, novel 
biomarkers that are capable of improving risk stratification and 
therapeutic decision-making are required. The present study 
aimed to evaluate the potential roles of two previously proposed 
biomarkers of tumour status: B-cell lymphoma 2 (Bcl-2) and 
β-catenin. A total of 412 patients undergoing surgery for 
primary colorectal cancer were studied. Tumour specimens 
of the patients were collected, fixed and processed for immu-
nohistochemical detection of Bcl-2 and β-catenin. The data 
were then analyzed in relation to disease-free survival and 
overall survival. Pathological stage was the only variable that 
was significantly correlated with both disease‑free and overall 
survival. The expression levels of neither Bcl‑2 nor β-catenin 
were able to accurately predict prognosis. However, there was 
a clear association between nuclear β‑catenin expression levels 
and disease-free survival in the three tumour stages. There was 
an increased hazard ratio in stage I and II nuclear β-catenin 
positive tumours, whereas there was a marked decrease in 
risk in stage III positive tumours. A similar effect was also 
observed with regards to overall survival, however this finding 
was not significant. The results of the present study suggest that 
conventional pathological tumour staging is the only accurate 
prognostic method. Neither Bcl-2 or β-catenin were shown to 
be useful biomarkers for the prognosis of colorectal cancer. 
However, the heterogeneous behaviour of nuclear β-catenin 
expression in the various tumour stages may indicate a possible 
role in predicting the response of patients to chemotherapy. 
Therefore, nuclear β‑catenin expression may be a biomarker 
for the prediction of improved responses to chemotherapy.
Introduction
Colorectal cancer (CRC) is a significant health problem world-
wide. It is the most common newly diagnosed cancer and the 
second most common cause of cancer-associated mortality in 
Europe, accounting for 436,000 cases and 212,000 deaths in 
2008 (1,2).
The prognosis of CRC markedly differs between the early 
and late stages of the disease. In stage I or II cancers, the 
postoperative five‑year recurrence rate is <30%, whereas in 
stage III cancer it is 60% (3,4). However, it is well‑known that 
patients with the same stage of disease may have substantially 
different outcomes. Specifically, a minority of patients with 
stage II CRC have a poor outcome. However, the identifica-
tion of this subset of patients remains unpredictable using the 
traditional staging system (5,6). Therefore, the identification 
of novel predictive factors that are capable of improving risk 
stratification and therapeutic decision‑making is required. A 
deeper insight into the basic genetic mechanisms that underlie 
the development of CRC may be beneficial for the identification 
of novel biomarkers. Noteworthy progress has been achieved in 
this area since 1990, when Fearon and Vogelstein (7) reported 
their multistep genetic model of colorectal tumourigenesis. 
According to this model, a series of genetic alterations, such 
as the activation of certain oncogenes and the inactivation of 
particular tumour suppressor genes, are responsible for the 
development of CRC. Two of the genes implicated in this 
process are B-cell lymphoma 2 (Bcl-2) and β-catenin.
Programmed cell death prevents the expansion of damaged 
cells, and may be induced by various signals, including 
irreparable DNA damage. Bcl-2 has a role in the prevention 
of apoptosis. Therefore, its overexpression may promote the 
survival of damaged cells (8). This may lead to the continued 
division of mutated cells and, ultimately, to carcinogenesis.
The Wnt/β-catenin signaling pathway has an important role 
in embryogenesis and tumorigenesis. The majority of cases of 
sporadic CRC and familial adenomatous polyposis exhibit 
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a mutated adenomatous polyposis coli (APC) gene (9). The 
non-mutated APC protein downregulates the Wnt signaling 
pathway by binding to β‑catenin and axin. However, the 
majority of mutated APC proteins in colorectal tumours fail to 
inhibit Wnt signaling, leading to over-proliferation of tumour 
cells (9). Furthermore, stabilized β-catenin translocates to the 
nucleus where it acts as a transactivation factor that promotes 
tumour growth (10,11).
The aim of the present study was to investigate whether over-
expression of Bcl‑2 and/or nuclear accumulation of β-catenin 
represent independent prognostic factors in non-advanced 
operable CRC. The present study also aimed to determine the 
association between Bcl-2 and β-catenin, and well-established 
clinicopathological risk stratification parameters.
Materials and methods
Patients. Patients with CRC were prospectively enrolled in 
the present study between June 1993 and September 2010. All 
patients undergoing curative surgical resection for primary 
CRC in the 2nd Urgency and General Surgery Unit (Careggi 
University Hospital, Florence, Italy) were considered eligible 
for the study. The exclusion criteria were as follows: Age 
>85 years, preoperative radiochemotherapy, distant metastases 
at diagnosis, hereditary non-polyposis colorectal cancer or 
familial adenomatous polyposis, or a personal history of other 
types of tumour. Patients in whom it was not possible to collect 
adequate tissue for biological determinations, or who did not 
survive past 30 days of surgery were also excluded.
Full informed consent was obtained from all of the patients 
following a thorough explanation of treatment options and the 
aims of the study.
All patients underwent standard surgery. A right hemi-
colectomy consisted of dividing the ileocolic and right colic 
vessels on the superior mesenteric axis, and a left hemico-
lectomy with anterior rectal resection consisted of dividing 
the inferior mesenteric artery at its origin, following identi-
fication of the para‑aortic left nervous trunk. Cancer staging 
was assessed according to the American Joint Committee on 
Cancer/Union for International Cancer Control Tumour Node 
Metastasis classification (12).
Tissue specimens and immunohistochemistry. In addition to 
the routine procedures for histopathological diagnosis, speci-
mens from the colorectal adenocarcinoma and from normal 
mucosa (at a 10 cm distance from the tumour) were collected 
from the patients immediately following surgery. The speci-
mens were then formalin‑fixed (37% formalin; Sigma-Aldrich, 
St. Louis, MO, USA) and paraffin blocks (Shandon; Thermo 
Fisher Scientific, Waltham, MA, USA) were prepared. The 
tissue specimens were then cut into 4-µm sections and mounted 
on glass slides coated with 3‑aminopropyltriethoxysilane 
(Sigma‑Aldrich, St. Louis, MO, USA), dewaxed in xylene and 
rehydrated with graded alcohols.
Prior to incubation with the primary antibodies, the 
sections were immersed in tris/EDTA buffer (pH=9.0; Dako, 
Glostrup, Denmark) and heated in a water bath (96˚C) for 
20 min. Following antigen retrieval, where the slides were 
immersed in buffer at pH 9.0 (Dako Cytomation) and incu-
bated at 96˚C for 20 min, the samples were allowed to cool 
at room temperature and washed with phosphate-buffered 
saline (PBS). Endogenous peroxidase was then blocked using 
peroxidase‑blocking reagent (Dako) for 5 min, followed by 
three washes with PBS.
Mouse anti-Bcl-2 monoclonal antibody (clone 124, dilution 
1:50; M0887; Dako), and mouse monoclonal anti‑β-catenin 
(clone β‑catenin‑1, dilution 1:200; M3539; Dako), were applied 
to the specimens for 30 min at room temperature, in a humidi-
fied chamber. The specimens were subsequently incubated 
with a secondary labelled polymer (Envision System Labelled 
Polymer‑Horseradish Peroxidase anti‑mouse; Dako) for 30 min 
at room temperature, and washed with PBS three times for 
3 min. Liquid 3-3'diaminobenzidine (Dako) plus substrate was 
then added for 5 min. Following further washing with PBS, 
the sections were lightly counter‑stained with hematoxylin 
and examined with a Leitz Laborlux binocular microscope 
(magnification, x25/0.5; Leica Microsystems GmbH, Wetzlar, 
Germany). Omission of the primary antibody acted as a 
negative control. Immunoreactivity for Bcl-2 was evaluated 
according to the percentage of tumour cells with positive 
cytoplasmic staining. A cut‑off value of 5% positive tumour 
cells was used to discriminate Bcl-2 negative from Bcl-2 posi-
tive cases. Infiltrating lymphocytes were classed as an internal 
positive control for immunoreactivity. Membranous (β-M), 
cytoplasmic (β-C) and nuclear (β-N) staining for β-catenin 
were each evaluated separately. The same cut‑off value of 5% 
positive tumour cells was used to discriminate negative from 
positive cases, with regard to β-catenin. Bcl-2 and β-catenin 
evaluations were performed independently by two authors of 
the present study (Dr Manuela Balzi and Dr Paola Faraoni), 
who were blinded to the pathological findings.
Statistical analysis. The distribution of the patients in the 
present study is reported with respect to their demographic, 
clinical and biological characteristics, which are summarized 
as frequencies or percentages. The presence of an association 
between the demographic, clinical and biological charac-
teristics was evaluated using a χ2 test for heterogeneity, and 
Fisher's exact test when appropriate. All of the variables 
were investigated in terms of their impact on the duration of 
disease-free survival (DFS), and overall survival (OS). DFS 
was defined as the interval between surgical intervention and 
disease recurrence, or death from any cause, depending on 
which occurred first. OS was defined as the time between 
intervention and end-of-life, regardless of the cause. The 
observation time of the patients who had not relapsed and 
were alive at the final follow‑up visit was censored. Median 
follow-up time and interquartile range (IQR) were estimated 
according to the Kaplan-Meier inverse method, as previ-
ously described (13). In the univariate analysis, estimates of 
DFS and OS were calculated according to the Kaplan-Meier 
product-limit method. Comparisons of the estimated survival 
curves were performed by means of a log-rank test. Hazard 
ratios (HR) and appropriate 95% confidence intervals (CI) 
were also calculated by means of the Cox proportional hazard 
model. A multivariate Cox regression model was fitted to 
evaluate the independent effect of each factor on both DFS 
and OS. Beginning with a full model, including gender, age 
at diagnosis, tumour site, clinical stage, histology, Bcl-2, β-M, 
β-N, β-C and adjuvant chemotherapy, variables which did not 
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exhibit significance were progressively removed using a back-
ward stepwise procedure, based on the likelihood ratio test. 
A probability of 0.05 was used for both removal and re-entry 
criteria. The presence of heterogeneity of the effect of a single 
predictor on DFS and OS in the various subgroups of patients 
was evaluated according to the results of an interaction test. 
All reported P‑values are two‑sided and P<0.05 was consid-
ered to indicate a statistically significant difference. Statistical 
analyses were performed by Luca Boni at the Istituto Toscano 
Tumouri using SAS System 9.2 (SAS Institute, Inc., Cary, NC, 
USA).
Results
Patients. During the study period 412 patients with CRC 
were enrolled. However, 91 patients were excluded due to 
absence or incompleteness of follow-up data, and/or the tech-
nical impossibility of assessing the biological markers. This 
Table I. Characteristics of the patients with CRC included and not included in the statistical analyses of the present study.
 Included Not included
 (n=321) (n=91)
 -------------------------------------------------- -------------------------------------------------
Variable N % N % P‑value
Gender
  Male 171 53.3 48 52.7 0.9296
  Female 150 46.7 43 47.3
Age (years)
  <60 79 24.6 21 23.1 0.7633
  ≥60 242 75.4 70 76.9
Tumor site
  Colon 200 62.3 49 53.8 0.1452
  Rectum 121 37.7 42 46.2
Pathological stage
  I 57 17.8 20 22 0.3418
  II 147 45.8 45 49.5
  III 117 36.4 26 28.6
Histology
  Adenocarcinoma 282 87.9 72 79.1 0.0346
  Colloid 39 12.1 19 20.9
Bcl-2
  Negative 168 52.3 27 29.7 0.0456
  Positive 153 47.7 12 13.2
  Missing cases - - 52 57.1
β-M
  Negative 29 9 - - 0.4813
  Positive 292 91 5 5.5
  Missing cases - - 86 94.5
β-N
  Negative 165 51.4 4 4.4 0.2041
  Positive  156 48.6 1 1.1
  Missing cases - - 86 94.5
β-C
  Negative 99 30.8 5 5.5 0.0010
  Positive  222 69.2 - -
  Missing cases - - 86 94.5
Adjuvant chemotherapy
  No 162 50.5 53 58.2 0.1900
  Yes 159 49.5 38 41.8
Bcl‑2, B‑cell lymphoma 2; β-M, membranous β‑catenin; β-N, nuclear β‑catenin; β-C, cytoplasmic β‑catenin; N, number.
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resulted in a study group of 321 patients for statistical analysis. 
No significant differences were observed in the demographic 
and clinicopathological characteristics of the patients in the 
study group, compared with the patients in the excluded 
group (Table I).
Bcl‑2 and β‑catenin findings. Positive immunohistochemical 
staining for Bcl‑2 was detected in 153 out of the 321 (47.7%) 
carcinoma specimens. Nuclear localization of β-catenin was 
detected in 156 cases (48.6%), with cytoplasmic and membrane 
localisation found in 222 (69.2%) and 292 (91.0%) cases, 
respectively. The association between Bcl-2 and β‑N expres-
sion, and the demographic and clinicopathological variables 
are presented in Table II. Bcl‑2 was expressed more frequently 
in pathological stage I tumors, compared with stage II or III 
tumours (P=0.069). There was also a significant association 
between Bcl‑2 expression and β‑C expression (P=0.048). β-N 
expression was more frequently observed in adenocarcinoma 
samples, compared with colloid carcinoma samples (50.7% vs 
33.3%, P=0.042). There was a significant association between 
the absence of β-M expression and the presence of β‑N expres-
sion, with 82.8% of β-M-negative tumours (compared with 
only 45.2% of β-M-positive cases) positive for β‑N expression 
(P<0.001). Tumours that were positive for β‑C expression were 
frequently also positive for β‑N expression (P<0.001).
Association between pathological and biomolecular vari‑
ables, and survival. Following surgery, follow-up data was 
collected from each patient according to the Associazione 
Italiana di Oncologia Medica guidelines (www.AIOM.it), with 
a median follow-up time of 5.3 years (IQR=3.0-7.2). Adjuvant 
chemotherapy, according to international guidelines (14), was 
Table II. Association between the expression of Bcl‑2 and nuclear β-N, and clinicopathological data.
 Immunohistochemical expression Immunohistochemical expression
 of Bcl-2 of β-N
 --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
Variable Negative (%) Positive (%) P‑value Negative (%) Positive (%) P‑value
All cases 168 (52.3) 153 (47.7) ‑ 165 (51.4%) 156 (48.6) ‑
Gender
  Male 89 (52.0) 82 (48.0) 0.912 87 (50.9) 84 (49.1) 0.841
  Female 79 (52.7) 71 (47.3)  78 (52.0) 72 (48.0) 
Age (years)
  <60 44 (55.7) 35 (44.3) 0.491 40 (50.6) 39 (49.4) 0.875
  ≥60 124 (51.2) 118 (48.8)  125 (51.7) 117 (48.3) 
Tumor site      
  Colon 102 (51.0) 98 (49.0) 0.538 103 (51.5) 97 (48.5) 0.964
  Rectum 66 (54.5) 55 (45.5)  62 (51.2) 59 (48.8) 
Pathological stage
  I 22 (38.6) 35 (61.4) 0.069 30 (52.6) 27 (47.4) 0.766
  II 80 (54.4) 67 (45.6)  78 (53.1) 69 (46.9) 
  III 66 (56.4) 51 (43.6)  57 (48.7) 60 (51.3) 
Histology
  Adenocarcinoma 150 (53.2) 132 (46.8) 0.41 139 (49.3) 143 (50.7) 0.042
  Colloid 18 (46.2) 21 (53.8)  26 (66.7) 13 (33.3) 
Bcl-2
  Negative N/A N/A N/A 94 (56.0) 74 (44.0) 0.087
  Positive    71 (46.4) 82 (53.6) 
β-M
  Negative 12 (41.4) 17 (58.6) 0.216 5 (17.2) 24 (82.8) <0.001
  Positive 156 (53.4) 136 (46.6)  160 (54.8) 132 (45.2) 
β-N
  Negative 94 (57.0) 71 (43.0) 0.087 N/A N/A N/A
  Positive 74 (47.4) 82 (52.6)    
β-C
  Negative 60 (60.6) 39 (39.4) 0.048 78 (78.8) 21 (21.2) <0.001
  Positive 108 (48.6) 114 (51.4)  87 (39.2) 135 (60.8)  
N/A, not applicable; Bcl‑2, B‑cell lymphoma 2; β-N, β‑catenin; β-M, membranous β‑catenin; β-C, cytoplasmic β-catenin.
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administered to 2 out of 57 (3.5%), 55 out of 147 (37.4%) and 
102 out of 117 (87.2%) patients with pathological stage I, II 
and III CRC, respectively. Five-year DFS and OS were 70 and 
80%, respectively, in the whole group of 321 patients.
The univariate analysis determined the associations 
between DFS and OS outcome variables, and demographic and 
clinicopathological characteristics (Table III). Pathological 
stage was the only variable that significantly affected both 
DFS and OS, with a progressively increasing risk of recur-
rence or death from pathological stage I to stage III (P<0.001). 
Furthermore, patients with colloid carcinoma had a slightly 
increased risk of recurrence (P=0.058) and death (P=0.047), 
compared with patients with adenocarcinoma.
A similar, although less evident trend was observed in the 
patients who underwent adjuvant chemotherapy, compared 
with untreated patients (P=0.048 and P=0.187 for DFS and OS, 
respectively). These results suggest that neither of the prospec-
tive biomarkers, including the various cellular localisations of 
β-catenin, was capable of distinguishing patients with a high 
risk of recurrence or death, from those with a better prognosis.
Multivariate analysis confirmed that pathological stage 
remained the only accurate predictor of locoregional and/or 
Table III. Univariate analysis of five‑year disease‑free survival and overall survival, in patients with CRC.
 Disease-free survival Overall survival
 (83 events) (55 events)
 --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
Variable N 5‑year % HR (95% CI) P‑value 5‑year % HR (95% CI) P‑value
All cases 321 70 - - 80 - -
Gender
  Male 171 68 1 (ref.) 0.472 79 1 (ref.) 0.437
  Female 150 73 0.85 (0.55-1.32)  81 0.81 (0.47-1.38) 
Age (years)
  <60 79 72 1 (ref.) 0.993 83 1 (ref.) 0.436
  ≥60 242 70 1.00 (0.60‑1.65)  79 1.30 (0.67‑2.52) 
Tumor site
  Colon 200 71 1 (ref.) 0.401 81 1 (ref.) 0.127
  Rectum 121 70 1.21 (0.78-1.87)  78 1.51 (0.89-2.56) 
Pathological stage
  I 57 87 1 (ref.) <0.001 93 1 (ref.) <0.001
  II 147 74 1.82 (0.80-4.14)  84 1.51 (0.56-4.08) 
  III 117 58 4.12 (1.86-9.14)  68 3.92 (1.53-10.1) 
Histology
  Adenocarcinoma 282 72 1 (ref.) 0.058 81 1 (ref.) 0.047
  Colloid 39 60 1.73 (0.97-3.08)  70 1.98 (1.00-3.93) 
Bcl-2
  Negative 168 66 1 (ref.) 0.254 78 1 (ref.) 0.603
  Positive 153 75 0.78 (0.50-1.20)  82 0.87 (0.51-1.48) 
β-M
  Negative 29 75 1 (ref.) 0.986 77 1 (ref.) 0.483
  Positive 292 70 1.01 (0.49-2.09)  80 0.75 (0.34-1.67) 
β-N
  Negative 165 70 1 (ref.) 0.69 80 1 (ref.) 0.936
  Positive 156 71 0.92 (0.60-1.41)  80 1.02 (0.60-1.74) 
β-C
  Negative 99 72 1 (ref.) 0.303 80 1 (ref.) 0.796
  Positive 222 69 1.31 (0.78-2.19)  80 1.09 (0.58-2.03) 
Adjuvant chemotherapy
  No 162 74 1 (ref.) 0.048 83 1 (ref.) 0.187
  Yes 159 67 1.55 (1.00-2.39)  76 1.43 (0.84-2.44)
CRC, colorectal cancer; β-M, membranous β‑catenin; β-C, cytoplasmic β‑catenin; CI, confidence interval; HR, hazard ratio; (ref.), reference 
group.
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distant recurrence (P<0.001), with an increasing risk of recur-
rence in patients with pathological stage II (HR=2.04, 95% CI 
0.87‑4.81) and III (HR=5.56, 95% CI 2.14‑14.45), compared 
with patients with stage I disease. The effect of stage on OS 
was (P<0.001) similar for the HR, which was 1.87 (95% CI 
0.66‑5.29) and 5.76 (95% CI 1.87‑17.67) in stage II vs I, and 
stage III vs I comparisons, respectively.
The association between β‑N expression and pathological 
stage is shown in Table IV. The prognostic impact of β-N 
positivity on DFS, adjusted for adjuvant chemotherapy admin-
istration, was heterogeneous in the three stages (P=0.050). 
In stage I cases, the risk of recurrence in patients with β-N 
positive tumours was more than double that of patients with 
β-N negative tumours. In stage II cases, there was only a 
slight increase in the HR for patients with β-N positive tumors 
compared with β-N negative tumours. By contrast, for patients 
with stage III disease, a marked reduction in the HR was 
observed in those with β-N positive tumors compared with 
those with β-N negative tumours. A similar heterogeneity of 
the effect of β-N on OS was also observed. However, these 
findings were not statistically significant.
The interaction between treatment with chemotherapy and 
β‑N expression in patients with pathological stage II CRC is 
shown in Table IV. In this subgroup, the increased DFS in 
the patients undergoing adjuvant chemotherapy appeared to 
be associated, although not significantly, with β-N positivity 
(HR: 0.65; 95% CI 0.21‑1.99).
Discussion
The results of the present study indicate that there is hetero-
geneity in terms of the prognostic impact of β‑N expression 
in the various stages of operable CRC. An increased risk of 
recurrence and death was observed in β-N positive cases for 
patients with stage I and II disease, whereas a reduced risk was 
observed in those with stage III disease. However, no potential 
reliable prognostic role for Bcl-2 and β‑catenin expression was 
demonstrated. Conversely, the pathological stage of disease 
was confirmed as an independent prognostic factor.
The present study was designed based upon the previous 
experience of this group in evaluating the prognostic role of 
potential biomarkers in breast, larynx and urinary bladder 
cancers (15-25). The current study aimed to identify novel 
biomarkers with a possible prognostic role in operable CRC. 
Therefore, patients with stage IV disease were excluded, 
in order to avoid the confounding effects of the aggressive 
behaviour of these tumours, and of the heterogeneous presen-
tation and treatment strategies that are specific to patients with 
metastatic disease.
Positive immunostaining for Bcl‑2 was observed in 47.7% 
of tumours, with a higher frequency in patients with patholog-
ical stage I compared with stage II or III patients. This finding 
was not statistically significant, although it was concordant 
with results from previous reports (26,27). Furthermore, the 
lack of prognostic significance of Bcl‑2 in the present study is 
also in accordance with the results of previous studies (28,29). 
However, a number of other studies have reported Bcl-2 
expression to be a favorable prognostic factor (26,27).
β‑catenin membrane positivity was detected in 91.0% 
of tissue specimens, whereas cytoplasmic and nuclear 
staining were less frequently observed (69.2% and 48.6%, 
respectively). Comparisons between the three cellular locali-
sations of β-catenin demonstrated that β-M negativity was 
more frequently associated with localisation to the nucleus 
Table IV. Effects of nuclear β-catenin (β‑N) expression and adjuvant chemotherapy on five‑year disease‑free survival and overall 
survival in various subgroups of patients with CRC.
A, Effect of β-N positivity vs. negativity according to pathological stage (321 cases)b
 Disease-free survival Overall survival
 ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
Variable HR (95% CI) P‑valuea HR (95% CI) P‑valuea
 83 events  55 events
Stage I 2.65 (0.51-13.6) 0.050 1.47 (0.25-8.82) 0.094
Stage II 1.26 (0.62-2.56)  1.99 (0.75-5.32)
Stage III 0.50 (0.28-0.91)  0.55 (0.27-1.10)
B, Effect of adjuvant chemotherapy vs. no treatment according to β‑N expression (147 pathological stage II cases)
 Disease-free survival Overall survival
 ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
Variable HR (95% CI) P‑valuea HR (95% CI) P‑valuea
 31 events  23 events
Negative 1.01 (0.35-2.92) 0.573 0.62 (0.11-3.41) 0.913
Positive 0.65 (0.21-1.99)  0.70 (0.19-2.60)
atest for interaction; bhazard ratio (HR) estimates adjusted for adjuvant chemotherapy. CI, confidence interval; β-N, β-catenin.
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(82.8%), and that β-C and β‑N were frequently co‑expressed 
or not expressed at all. This pattern of expression confirms a 
previously reported association between the integrity of the 
APC‑complex and the normal turnover of β-catenin (30).
The present study provided no evidence to suggest an 
association between β-catenin positivity/negativity, and DFS 
and OS in CRC. Conversely, previous reports have suggested 
a favorable and unfavorable prognostic role for β-M and β-N 
expression, respectively (31-39). However, a notable finding 
from the present study was the differential prognosis associ-
ated with β‑N expression at particular pathological stages 
of disease, on DFS and OS. In stage I disease, positive β-N 
expression was shown to be associated with an increased risk 
of recurrence and death. A similar association was observed, 
although the results were not statistically significant, in 
patients with stage II. By contrast, in stage III CRC, β-N 
positivity was associated with a better prognosis. The data 
were adjusted for adjuvant chemotherapy, as the proportion 
of patients receiving this treatment was different in all three 
stages. These results may be partly attributable to an increased 
sensitivity of β-N positive tumours to chemotherapy. This 
hypothesis is supported by the previous demonstration of the 
participation of β-N in activating the transcription of genes 
involved in proliferation (10,40). The present results suggest 
that more rapidly proliferating tumors are associated with a 
worse prognosis, but may also represent a more favorable target 
for adjuvant chemotherapy (41). β‑N expression may therefore 
be a more reliable indicator of potential proliferation, and 
consequently of disease aggressiveness, compared with other 
markers, such as Ki‑67, as it does not appear to be influenced 
by tumour microenviromental factors as it function at a gene 
transcriptional level.
In order to verify this hypothesis and to improve under-
standing regarding the predictive role of β-N in the prognosis 
of CRC, the effects of chemotherapy on DFS and OS, in 
relation to β-N status, were studied in patients with stage II 
disease. Stage II CRC was the only stage that allowed for 
such a statistical analysis, due to the fact that there were 
approximately equal numbers of patients who did or did 
not receive adjuvant chemotherapy. A more beneficial effect 
(risk of relapse) of adjuvant therapy on DFS was associated 
with β‑N expression, although this finding was not statisti-
cally significant. A similar effect was not observed for OS. 
This discrepancy may be due to the compensatory effect of 
chemotherapy on OS, which was started in the majority of 
cases following recurrence.
The results of the present study suggest that the expres-
sion of β-N in cancer cells may be a potential novel marker of 
a more favourable response to chemotherapy. However, due 
to the small number of observed events in the present study 
this finding should be interpreted with caution, and requires 
further investigation.
In conclusion, the present study indicates that patho-
logical stage is the only independent variable that predicts 
DFS and OS in non-metastatic operable CRC. Neither of 
the biomarkers studied had a similar prognostic value. 
Furthermore, although these data require confirmation, the 
heterogeneity of the prognostic impact of nuclear β-catenin in 
the different stages may suggest a possible role in predicting 
the response of a tumour to chemotherapy.
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